New information flows for cancer registries: testing the use of laboratory data in the province of Reggio Emilia, Italy.


Journal

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837

Informations de publication

Date de publication:
11 2020
Historique:
entrez: 6 10 2020
pubmed: 7 10 2020
medline: 31 8 2021
Statut: ppublish

Résumé

Haematological malignancies often escape the standard information flows of cancer registries because diagnosis is not always based on bone marrow histology but, rather, on other laboratory tests. To quantify incident haematological malignancies identified exclusively through the laboratory information system and to measure the impact of that source on the sensitivity and accuracy of registering these malignancies. We collected data from the only provincial laboratory of Reggio Emilia on molecular biology, flow cytometry tests and bone marrow smears to detect specific markers of some chronic haematological malignancies. We carried out a record linkage between laboratory reports (period 2013-2017) of patients resident in the province of Reggio Emilia and the Cancer Registry of Reggio Emilia. Of the 303 patients who underwent at least one of these tests, 85 were not included in our Cancer Registry. Of these 85 patients, 42 had received a diagnosis of cancer: 34 myeloproliferative neoplasms, 3 chronic myeloid leukaemias, 3 myelodysplastic neoplasms, 1 multiple myeloma and 1 chronic lymphocytic leukaemia. We recovered 4.2% of the total number of chronic haemolymphopoietic cancers registered in the study period, accounting for 15% of myeloproliferative neoplasms. For 30% of prelinkage cases, the specificity of the morphological code improved. Although the laboratory information system's contribution to the completeness of Cancer Registry incident cases was modest, it is useful to add laboratory data to routine cancer registry information flows due to the increasing use of molecular characterisation and to the phenomenon of dehospitalisation.

Identifiants

pubmed: 33021768
doi: 10.1097/CEJ.0000000000000585
pii: 00008469-202011000-00012
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

548-555

Références

Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015; 5:e337
Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009; 45:747–755
Busco S, Buzzoni C, Mallone S, Trama A, Castaing M, et al.; Airtum Working Group. I Tumori in Italia – Rapporto AirTUM 2015 I tumori rari in Italia. Epidemiol Prev. 2016; 401 Suppl 2
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87:4990–4997
Coviello V, Buzzoni C, Fusco M, Barchielli A, Cuccaro F, De Angelis R, et al. I Tumori in Italia, Rapporto AirTUM 2016. La sopravvivenza dei pazienti oncologici in Italia. Epidemiol Prev. 2017; 412 Suppl 11–244
Vignot S, Tossen G, Solub D, Wilkowsky C; EMC – AKOS – Trattato di MedicinaTerapie Molecolari Mirate A, First Edn. 2016Elsevier1–7. https://www.em-consulte.com/it/article/1035949/terapie-molecolari-mirate.
Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. ICD-0 3 Classificazione Internazionale delle Malattie per l’Oncologia. 2005Terza edizione, Milano: Inferenze Scarl
Fung JW, Lim SB, Zheng H, Ho WY, Lee BG, Chow KY, Lee HP. Data quality at the Singapore cancer registry: an overview of comparability, completeness, validity and timeliness. Cancer Epidemiol. 2016; 43:76–86
Gavin A, Rous B, Marcos-Gragera R, Middleton R, Steliarova-Foucher E, Maynadie M, et al.; European Network of Cancer Registries. Towards optimal clinical and epidemiological registration of haematological malignancies: guidelines for recording progressions, transformations and multiple diagnoses. Eur J Cancer. 2015; 51:1109–1122
Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues WHO Classification of Tumours. 20013rd ed, Lyon: Edition International Agency for Research on Cancer
James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005; 11:546–554
Jensen OM, Parkin DM, Mac Lennan R, Muir CS, Skeet RG. Cancer Registration, Principles and Methods. 1991, Lyon: IARC Scientific publications
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369:2379–2390
Leinonen MK, Miettinen J, Heikkinen S, Pitkäniemi J, Malila N. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017; 77:31–39
Lorez M, Bordoni A, Bouchardy C, Bulliard JL, Camey B, Dehler S, et al. Evaluation of completeness of case ascertainment in Swiss Cancer Registration. Eur J Cancer Prev. 2017; 26 Joining forces for better cancer registration in Europe:S139–S146
Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960; 25:85–109
Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL. Comparability and quality control in cancer registration. 1994, Lyon: IARC (WHO) and IACR. IARC technical report no. 19
Passamonti F, Mora B, Maffioli M. New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. Curr Opin Hematol. 2016; 23:137–143
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Plos Med. 2006; 3:e270
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15:e538–e548
Regione Emilia Romagna. Nomenclatore tariffario regionale versione secondo la classificazione ICD-IX. 2019. Available at http://salute.regione.emilia-romagna.it/ssr/strumenti-e-informazioni/nomenclatore-tariffario-rer. [Accessed 01 September 2019]
Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al.; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116:3724–3734
Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al.; EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014; 15:931–942
Simonsson B, Kloke O, Stahel RA; ESMO Guidelines Task Force. ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). Ann Oncol. 2005; 16Suppl 1i52–i53
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 20084th ed, Lyon: International Agency for Research on Cancer
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues WHO Classification of Tumours. 20164th rev. ed, Lyon: International Agency for Research on Cancer
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100:2292–2302
Wanner M, Matthes KL, Korol D, Dehler S, Rohrmann S. Indicators of data quality at the cancer registry Zurich and Zug in Switzerland. Biomed Res Int. 2018; 2018:7656197
Zahid MF, Parnes A, Savani BN, Litzow MR, Hashmi SK. Therapy-related myeloid neoplasms – what have we learned so far? World J Stem Cells. 2016; 8:231–242

Auteurs

Francesca Roncaglia (F)

Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia.
Laboratory of Medical Statistics, Biometry and Epidemiology 'G.A. Maccacaro', Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano.

Pamela Mancuso (P)

Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia.

Massimo Vicentini (M)

Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia.

Antonio Vitiello (A)

IT Department, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia.

Luigi Vecchia (L)

Clinical Chemistry and Endocrinology Laboratory.

Stefano Luminari (S)

Hematology Unit, Azienda USL-IRCCS di Reggio Emilia.
CHIMOMO Department University of Modena & Reggio Emilia, Modena.

Lucia Mangone (L)

Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia.

Manuel Zorzi (M)

Veneto Tumour Registry, Azienda Zero, Padova, Italy.

Carlo La Vecchia (C)

Laboratory of Medical Statistics, Biometry and Epidemiology 'G.A. Maccacaro', Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano.

Paolo Giorgi Rossi (P)

Epidemiology Unit, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH